PURE Bioscience, Inc. (PURE)
OTCMKTS · Delayed Price · Currency is USD
0.0650
0.00 (0.00%)
Aug 5, 2026, 2:56 PM EST

PURE Bioscience Financials Overview

Millions USD. Fiscal year is Aug - Jul.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingApr '26 Jul '25 Jul '24 Jul '23 Jul '22 Jul '21
Revenue
2.422.21.961.881.853.93
Revenue Growth
26.67%12.17%4.58%1.29%-52.81%-43.23%
Gross Profit
1.431.31.150.9712.08
Operating Income
-1.92-2.27-3.13-3.63-3.37-2.31
Net Income
-2.21-2.4-3.35-3.96-3.49-2.32
Earnings Per Share
-0.02-0.02-0.03-0.04-0.04-0.03
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingApr '26 Jul '25 Jul '24 Jul '23 Jul '22 Jul '21
Cash & Investments
0.980.330.351.13.392.39
Total Debt
6.55.242.951.02-0.24
Net Cash (Debt)
-5.51-4.9-2.60.073.392.15
Net Cash Growth
----97.82%57.65%-43.97%
Net Cash Per Share
-0.05-0.04-0.020.000.040.02

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingApr '26 Jul '25 Jul '24 Jul '23 Jul '22 Jul '21
Operating Cash Flow
-1.78-2.02-2.53-3.28-2.42-1.17
Capital Expenditures
----0.03-0.08-0.52
Free Cash Flow
-1.78-2.02-2.53-3.31-2.5-1.69
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingApr '26 Jul '25 Jul '24 Jul '23 Jul '22 Jul '21
Gross Margin
58.84%59.17%58.69%51.73%53.97%52.84%
Operating Margin
-79.11%-103.18%-159.50%-193.29%-181.87%-58.85%
Pretax Margin
-91.04%-108.95%-170.66%-211.03%-188.40%-59.05%
Profit Margin
-91.04%-108.95%-170.66%-211.03%-188.40%-59.05%
FCF Margin
-73.49%-91.51%-128.94%-176.40%-134.86%-42.98%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Jul '25 Jul '24 Jul '23 Jul '22 Jul '21
PS Ratio
3.494.564.555.0712.009.33